Steroid-resistant nephrotic syndrome
MONDO:0044765Nephrotic syndrome, occurring in the pediatric population, in which proteinuria does not normalize with administration of steroids; this condition is unresponsive to a minimum of four weeks administration of oral corticosteroids.
Also known as: nephrotic syndrome of childhood - steroid resistant, nephrotic syndrome-steroid-resistant, steroid-resistant nephrotic syndrome, nephrotic syndrome, idiopathic, steroid-resistant, nephrotic syndrome, steroid-resistant, autosomal recessive, NPHS2, SRNS - steroid-resistant nephrotic syndrome, steroid-unresponsive nephrotic syndrome
17 clinical trials for this condition and its sub-types, 5 tagged with Steroid-resistant nephrotic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Steroid-resistant nephrotic syndrome
-
Nephrotic syndrome 14 3 trials
-
Sporadic idiopathic steroid-resistant nephrotic syndrome 0 trials · 2 incl. sub-types
3 sub-types
-
14 sub-types
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Focal segmental glomerulosclerosis 1 0 trials
- Nephrotic syndrome, type 10 0 trials
- Nephrotic syndrome, type 11 0 trials
- Nephrotic syndrome, type 12 0 trials
- Nephrotic syndrome, type 13 0 trials
- Nephrotic syndrome, type 2 0 trials
- Nephrotic syndrome, type 3 0 trials
- Nephrotic syndrome, type 6 0 trials
- Nephrotic syndrome, type 8 0 trials
- Nephrotic syndrome, type 9 0 trials
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
One infusion may keep childhood kidney disease at bay — a trial puts it to the test
Disease control Not yet recruitingThis trial tests whether adding a single infusion of zuberitamab to standard steroid therapy can help children aged 1 to 18 with newly diagnosed steroid-sensitive nephrotic syndrome stay relapse-free longer. Participants receive either standard steroids alone or steroids plus zub…
Phase 3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug may help kids with kidney disease avoid relapses
Disease control Not yet recruitingThis study tests whether one or two doses of ripertamab can help children aged 16 and older who have frequent relapses or steroid-dependent nephrotic syndrome. The goal is to see which dose works better at preventing relapses and reducing the need for steroids. The trial will enr…
Sponsor: Mao Jianhua • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC